Q32 Bio Inc.
Q32 Bio is a clinical stage biotechnology company dedicated to developing biologic therapeutics that restore immune homeostasis in autoimmune and inflammatory diseases. Their mission is to transform the lives of patients by targeting key regulators of the immune system, including the IL-7/TSLP receptor pathways and the complement system. They focus on innovative therapies such as anti-IL-7Rα antibodies and tissue-targeted complement inhibitors, with multiple programs in clinical development, including Phase 2 trials for conditions like alopecia areata, atopic dermatitis, and complement-mediated diseases.
Industries
Nr. of Employees
small (1-50)
Q32 Bio Inc.
Products
Monoclonal antibody therapeutic targeting IL-7Rα (clinical-stage)
A fully human antagonistic monoclonal antibody directed at IL-7Rα designed to block IL-7 and TSLP-mediated signaling to re-regulate adaptive immune function; advanced through Phase 1 and into Phase 2 clinical trials for autoimmune dermatologic indications.
Tissue-targeted complement inhibitor fusion protein (first-in-human completed)
A fusion protein that links a tissue-deposited complement fragment–binding antibody domain to complement regulatory protein fragments to inhibit alternative pathway complement activity in diseased tissues while avoiding systemic complement blockade; completed Phase 1 and planned Phase 2 renal and vasculitis studies.
Monoclonal antibody therapeutic targeting IL-7Rα (clinical-stage)
A fully human antagonistic monoclonal antibody directed at IL-7Rα designed to block IL-7 and TSLP-mediated signaling to re-regulate adaptive immune function; advanced through Phase 1 and into Phase 2 clinical trials for autoimmune dermatologic indications.
Tissue-targeted complement inhibitor fusion protein (first-in-human completed)
A fusion protein that links a tissue-deposited complement fragment–binding antibody domain to complement regulatory protein fragments to inhibit alternative pathway complement activity in diseased tissues while avoiding systemic complement blockade; completed Phase 1 and planned Phase 2 renal and vasculitis studies.
Services
Collaborative clinical development and program management
Operational management and execution of clinical development activities under collaboration or funding agreements with pharmaceutical partners; includes conduct of Phase 1 and Phase 2 studies and biomarker-enabled trials.
CMC strategy and manufacturing development support
Strategic planning and operational oversight of CMC activities to advance clinical-stage therapeutics, including manufacturing strategy, process development and coordination of CMC deliverables for regulatory filings.
Collaborative clinical development and program management
Operational management and execution of clinical development activities under collaboration or funding agreements with pharmaceutical partners; includes conduct of Phase 1 and Phase 2 studies and biomarker-enabled trials.
CMC strategy and manufacturing development support
Strategic planning and operational oversight of CMC activities to advance clinical-stage therapeutics, including manufacturing strategy, process development and coordination of CMC deliverables for regulatory filings.
Expertise Areas
- Clinical trial management
- Antibody therapeutics development
- Tissue-targeted complement therapeutics
- Preclinical in vivo pharmacology
Key Technologies
- Monoclonal antibody therapeutics
- Fusion protein therapeutics
- C3d-mediated tissue targeting
- Tissue-targeted complement inhibition